Early Briefing and Review: Bristol-Myers Squibb Co., Eli Lilly & Co., Allergan Inc., and Endo Health Solutions Inc.

LONDON, August 12, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

On Friday, August 9, 2013, the S&P 500 closed 0.36% lower at 1,691.42. Shares in drug manufacturing companies ended mostly lower as the broader market ended on a declining note. The major movers in the sector included Bristol-Myers Squibb Company (NYSE:BMY), Eli Lilly and Company (NYSE: LLY), Allergan Inc. (NYSE: AGN), and Endo Health Solutions Inc. (NASDAQ: ENDP). AAAResearchReports.com has released free charting and technical research on these aforementioned companies. Register to read these reports at:

http://www.aaaresearchreports.com/register/  

Shares in Bristol-Myers Squibb Company moved lower on Friday as the broader market ended on a declining note. The company's shares ended the day 0.70% lower at $43.69 after fluctuating between $43.49 and $44.10. A total of 4.19 million shares were traded, which is significantly below the daily average volume of 10.27 million. The company's shares have gained 7.90% in the last three months, outperforming the S&P 500 which has gained 3.53% during the same period. However, the stock is trading below its 50-day moving average. Sign up for free report on BMY at:

http://www.AAAResearchReports.com/BMY081213.pdf

Shares in Eli Lilly and Company rose sharply on Friday, finishing at $54.18, up 1.14% from the previous closing price. The company's shares fluctuated between $53.35 and $54.21. A total of 14.72 million shares were traded, which is significantly above the daily average volume of 5.57 million. The stock has gained 1.61% in the last three trading sessions and 5.12% in the last one month, outperforming the S&P 500. Further, Eli Lilly's shares are trading above their 50-day and 200-day moving averages. LLY free technical report can be accessed by signing up at:

http://www.AAAResearchReports.com/LLY081213.pdf

Shares in Allergan Inc. fell sharply on Friday, reversing some of their recent gains. The company's shares closed at $91.10, down 1.30% from the previous closing price. Allergan's stocks fluctuated between $91.05 and $92.58. A total of 1.16 million shares were traded, which is below the daily average volume of 2.71 million. However, in the last one month, the stock has gained 1.87%, outperforming the S&P 500 which has gained 0.67% during the same period. A free report on AGN can be accessed by registering at:

http://www.AAAResearchReports.com/AGN081213.pdf

Shares in Endo Health Solutions Inc. ended nearly flat on Friday as the broader market declined. The company's shares fluctuated between $36.54 and $37.01 before finishing the day at $36.81, down 0.03%. A total of 1.06 million shares were traded, which is below the daily average volume of 1.87 million. However, in the last three months, the stock has gained 5.26%, outperforming the S&P 500 which was up 3.53% during the same period. Register with AAA Research Reports and download research on ENDP for free at:

http://www.AAAResearchReports.com/ENDP081213.pdf

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA ® charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
  5. For any urgent concerns or inquiries, please contact us at [email protected].
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


AAAresearchreports.com

SOURCE AAA Research Reports

Suggested Articles

Creating a relevant online health user experience has its payoffs — for both the user and the brand. Here’s why.

Sanofi's new strategy delivered for the drugmaker in the third quarter as Dupixent posted blockbuster sales and flu vaccines set a revenue record.

Catalent has acquired Bone Therapeutics' cell and gene therapy site in Gosselies, Belgium, to add to its growing "center of excellence" there.